An interventional study of SEDA in Hearing Impairment, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hearing Loss by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss · NYU Langone Health.
Among the 10 studies in Hearing Loss by NYU Langone Health, this one has the largest planned enrollment, is one of 2 that started in 2023, is one of 10 with no phase, and was the 6th registered.
797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →6 of the 10 studies in Hearing Loss by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18 mo–21 yrs
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 16+
By country, each count listing its studies:
Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 60 is above the median of 44 across 562 interventional studies indexed under Hearing Loss.
Median enrollment 14 across the 10 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
2 of the studies in Hearing Loss by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06663917NYU Langone HealthClinical Evaluation of Frequency Allocation for Bimodal CI Users | 2027-10-06 |
| NCT05805384NYU Langone HealthEvaluating a Noise Reduction Algorithm With Cochlear Implant Users | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Hearing Loss by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, a noise reduction algorithm will be implemented in various listening situations to evaluate its effectiveness in improving speech understanding for cochlear implant users ages 12 and older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will complete up to 4 experiments evaluating the use of the Speech Enhancement using Dynamic thresholding Approach (SEDA) algorithm. Each testing session will take between 4-6 hours to complete. Testing sessions will continue until the completion of the experiments.
Device: SEDA
Speech Enhancement using Dynamic thresholding Approach (SEDA) is a software algorithm that removes background noise.
Percent of Words Correctly Recognized in Noisy Conditions with SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions while using the SEDA Noise Reduction (NR) algorithm.
Time frame: Up to Year 2 (Completion of Experiment 1.1)
Percent of Words Correctly Recognized in Noisy Conditions without NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions without SEDA NR.
Time frame: Up to Year 2 (Completion of Experiment 1.1)
Percent of Words Correctly Recognized in Quiet Conditions with SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quiet listening conditions while using the SEDA NR.
Time frame: Up to Year 2 (Completion of Experiment 1.1)
Percent of Words Correctly Recognized in Quiet Conditions without NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quiet listening conditions with SEDA NR.
Time frame: Up to Year 2 (Completion of Experiment 1.1)
Visual Analogue Scale (VAS) Rating of SEDA NR
Participants will be presented with two buttons: one button will play a sample with SEDA NR and the other will play a sample without SEDA NR. Listeners will report which sample was preferable by clicking on a horizontal visual analog scale (VAS). VAS ratings will be scored on a scale of -10 to 10 where positive numbers indicate a preference for SEDA NR and negative numbers indicate a preference for not using SEDA NR. The magnitude of the absolute value of the score indicates the strength of the preference.
Time frame: Up to Year 2 (Completion of Experiment 1.2)
Percent of Words Correctly Recognized in Noisy Conditions with Clinical NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in noisy listening conditions while using a clinical NR algorithm.
Time frame: Up to Year 2 (Completion of Experiment 2)
Percent of Words Correctly Recognized in Quiet Conditions with Clinical NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized in quite listening conditions while using a clinical NR algorithm.
Time frame: Up to Year 2 (Completion of Experiment 2)
Percent of Words Correctly Recognized with no SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized without SEDA NR.
Time frame: Up to Year 2 (Completion of Experiment 4)
Percent of Words Correctly Recognized with Standard SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with Standard SEDA NR.
Time frame: Up to Year 2 (Completion of Experiment 4)
Percent of Words Correctly Recognized with Low-Computation SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with the Low-Computation SEDA NR, which is designed to have minimal computation while maintaining an Extended Short-Time Objective Intelligibility Predictor (ESTOI) value similar to the "standard" SEDA implementation
Time frame: Up to Year 2 (Completion of Experiment 4)
Percent of Words Correctly Recognized with Very Low-Computation SEDA NR
Participants will listen to sentences and repeat all the words they heard. This outcome measures the percent of words correctly recognized with the Very Low-Computation SEDA NR, which is designed to have a reasonable ESTOI value with minimal computational requirements.
Time frame: Up to Year 2 (Completion of Experiment 4)
Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David.landsberger@nyulangone.com. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.landsberger@nyulangone.com. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Nov 2027, 56 months after the start.
Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 56 months is above that.
Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Mar 2027 → Nov 2027 and completion Mar 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.